Azido-PEG7-amine

Cat. No.:	HY-130324
CAS No.:	1333154-77-0
Molecular Formula:	$C_{16}H_{34}N_4O_7$
Molecular Weight:	394.46
Target:	ADC Linker; PROTAC Linkers
Pathway:	Antibody-drug Conjugate/ADC Related; PROTAC
Storage:	-20°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



SOLVENT & SOLUBILITY

In Vitro

H_2O : 100 mg/mL (253.51 mM; Need ultrasonic)
DMSO : 100 mg/mL (253.51 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.5351 mL	12.6756 mL	25.3511 mL
	5 mM	0.5070 mL	2.5351 mL	5.0702 mL
	10 mM	0.2535 mL	1.2676 mL	2.5351 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: PBS
   Solubility: 120 mg/mL (304.21 mM); Clear solution; Need ultrasonic
2. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (6.34 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (6.34 mM); Clear solution
4. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (6.34 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Azido-PEG7-amine is a non-cleavable 7 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Azido-PEG7-amine is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs[1]. Azido-PEG7-amine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

IC_{50} & Target	Non-cleavable Linker	PEGs
In Vitro	ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins. MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

REFERENCES

[1]. Kevin W. Gillman, et al. Macrocyclic peptides useful as immunomodulators. WO2016077518A1.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA